PLIVA d.d. (LSE: PLVD) today announced a deal in which it has reached agreement with GlaxoSmithKline (GSK) for the purchase of PLIVA – Istraživački Institut d.o.o. (PLIVA – Research Institute Ltd.), PLIVA’s proprietary R&D arm renowned for its research into macrolides, in Zagreb, Croatia. In May 2005, PLIVA announced its strategic intent to completely focus on its generics operations and exit the proprietary business. Following the divestments of the majority of PLIVA’s US proprietary business and Research Institute in Zagreb, PLIVA has now successfully completed its strategic objective of exiting the proprietary segment.